Clinical Decisions: Selecting the Right Disease Modifying Therapy

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Selecting the most appropriate Disease Modifying Therapy (DMT) is becoming more complicated for patients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/risk equation, and making the question of which treatment is most appropriate for which patient more difficult to answer. 

That’s the focus of our discussion with Dr. Erin Longbrake, Assistant Professor of Neurology and Director of the Multiple Sclerosis Fellowship Program at Yale University, in this eMultipleSclerosis Review podcast. 

Patients’ DMT Decision-Making

Volume 2, Issue 4

In this issue, Dr. Ellen Mowry, Associate Professor of Neurology and Epidemiology at the Johns Hopkins University School of Medicine, brings recent findings about patient decision-making and addressing common comorbidities into the MS clinic.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Clinical Markers for MS Diagnosis and Prognosis

Volume 2, Issue 2

The central vein sign. Optical coherence tomography. Serum neurofilament light chain. New research has identified these markers as valuable in discriminating MS from mimicking conditions, and in predicting future disability.

In this Issue, Dr. Michael Kornberg and Dr. Elias Sotirchos from the Johns Hopkins University School of Medicine discuss how these advances can impact clinical decision-making to provide better patient care.

Take our post-test to claim CME credits.

To read a companion newsletter click here.